Clinical Trial Alert

Nephrology Times:
doi: 10.1097/01.NEP.0000394225.63353.10
Clinical Trial Alert
    Back to Top | Article Outline
    • Acute Kidney Injury •

    NCT01227122

    NGAL Predictive Value of Acute Kidney Failure After Cardiac Surgery in Patients with Preoperative Chronic Kidney Failure

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Hôpital Jean Minjoz

    Contact: Sidney Chocron, MD, PhD

    Phone: 33381668662

    E-mail: sidney.chocron@univ-fcomte.fr

    Back to Top | Article Outline
    • Anemia •

    NCT00436748

    Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects with Chronic Kidney Disease

    Ages eligible for study: 1 year to 18 years

    Sponsors and collaborators: Amgen

    Contact: Amgen Call Center

    Phone: 866-572-6436

    NCT01235936

    Safety and Efficacy Study for AKB-6548 in Subjects with Chronic Kidney Disease and Anemia

    Ages eligible for study: 18 years to 79 years

    Sponsors and collaborators: Akebia Therapeutics

    Contact: Akebia Call Center

    Phone: 855-252-6548

    E-mail: AKB6548@akebia.com

    NCT00838097

    EU Registry in Pediatric CKD Patients Looking at Safety and Usage Patterns of Darbepoetin Alfa

    Ages eligible for study: Up to 16 years

    Sponsors and collaborators: Amgen

    Contact: Amgen Call Center

    Phone: 866-572-6436

    NCT00925587

    Study Evaluating Once-Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-Dialysis Patients with Chronic Kidney Disease

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Amgen

    Contact: Amgen Call Center

    Phone: 866-572-6436

    Back to Top | Article Outline
    • Autosomal Dominant Polycystic Kidney Disease •

    NCT01223755

    Sirolimus in Autosomal Dominant Polycystic Kidney Disease and Severe Renal Insufficiency

    Ages eligible for study: 18 years to 80 years

    Sponsors and collaborators: Mario Negri Institute for Pharmacological Research

    Contact: Norberto Perico, MD

    Phone: 0039 035 45351

    E-mail: norberto.perico@marionegri.it

    NCT00571909

    Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Mayo Clinic

    Contact: Marie C. Hogan, MD, PhD

    Phone: 507-266-1963

    E-mail: hogan.marie@mayo.edu

    Back to Top | Article Outline
    • Chronic Kidney Disease •

    NCT01194154

    A Study of Mircera in Patients with Chronic Kidney Disease (PRIMAVERA)

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Hoffmann-La Roche

    Contact: Please reference Study

    ID Number: ML22916

    Phone: 888-662-6728

    E-mail: genentechclinicaltrials@druginfo.com

    NCT01120314

    Pharmacokinetic, Pharmacodynamic, and Tolerability Study of Otamixaban in Patients with Severe Renal Impairment

    Ages eligible for study: 18 years to 79 years

    Sponsors and collaborators: Sanofi-Aventis

    E-mail: Contact-Us@sanofi-aventis.com

    NCT01237899

    Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Effect on Renal Potassium Clearance

    Ages eligible for study: 18 years to 65 years

    Sponsors and collaborators: Eli Lilly and Company

    Phone: 877-CTLILLY (877-285-4559)

    NCT01232010

    Clinical Study to Investigate the Safety and Pharmacokinetics of SK3530 Tablet in Renal-Impaired Male Patients

    Ages eligible for study: 19 years to 64 years

    Sponsors and collaborators: Asan Medical Center and SK Chemicals Co.

    Contact: Kyun-Seop Bae, MD, PhD

    Phone: 02-3010-4622

    Back to Top | Article Outline
    • Chronic Kidney Disease–Mineral and Bone Disorder •

    NCT01214356

    Impact of Vitamin D on Diabetic Kidney Disease in African-Americans

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Medical University of South Carolina

    Contact: Vanessa A. Diaz, MD, MS

    Phone: 843-792-7241

    E-mail: diazva@musc.edu

    Contact: Tara M. Hogue

    Phone: 843-792-0800

    E-mail: hoguetm@musc.edu

    NCT00745719

    Parathyroidectomy in End-Stage Renal Disease

    Ages eligible for study: 18 years to 80 years

    Sponsors and collaborators: University of Hong Kong

    Contact: Angela Y. M. Wang, MD, PhD

    Phone: 28554111, ext 4949

    E-mail: aymwang@hku.hk

    NCT00587158

    Oral Paricalcitol in Kidney Transplant Recipients

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Mayo Clinic and Abbott

    Contact: Rhette S. Lambert

    Phone: 480-342-1335

    E-mail: lambert.rhette@mayo.edu

    Contact: Misty M. Berndt

    Phone: 507-583-4071

    E-mail: berndt.misty@mayo.edu

    NCT00893451

    Study of Vitamin D3 Supplementation in Patients with Chronic Kidney Disease

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Sahlgrenska University Hospital, Sweden

    Contact: Hamid R. Dezfoolian, MD

    Phone: 46704948377

    E-mail: hamid.dezfoolian@vgregion.se

    Contact: Maria Svensson, PhD

    E-mail: maria.svensson@wlab.gu.se

    NCT01003275

    Metabolic Effects of Paricalcitol

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: University of Washington and Abbott

    Contact: Ian H. de Boer, MD, MS

    Phone: 206-616-5403

    E-mail: deboer@u.washington.edu

    Back to Top | Article Outline
    • Diabetes •

    NCT01113801

    A Study in Patients with Diabetic Kidney

    Disease

    Ages eligible for study: 25 years and older

    Sponsors and collaborators: Eli Lilly and Company, and Collaborative Study Group

    Contact: Eli Lilly and Company

    Phone: 877-CTLILLY (877-285-4559)

    NCT00175721

    Trial Comparing Care in Multiple Clinics Versus Care in a Cardiac, Diabetes, and Kidney Care Clinic

    Ages eligible for study: 18 years to 85 years

    Sponsors and collaborators: University of British Columbia

    Contact: Katy Vela

    Phone: 604-682-2344, ext. 69460

    E-mail: kvela@providencehealth.bc.ca

    Contact: Sarah Noble

    Phone: 604-682-2344, ext. 62510

    E-mail: snoble@providencehealth.bc.ca

    NCT01213212

    Preventing Renal Functional Abnormalities with Calorie Restriction in Subjects with Abdominal Obesity and Type 2 Diabetes at Increased Renal and Cardiovascular Risk

    Ages eligible for study: 40 years to 80 years

    Sponsors and collaborators: Mario Negri Institute for Pharmacological Research and Istituto Superiore di Sanita

    Contact: Piero Ruggenenti, MD

    Phone: 003903545351

    E-mail: piero.ruggenenti@marionegri.it

    NCT01064414

    An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients with Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

    Ages eligible for study: 25 years and older

    Sponsors and collaborators: Johnson & Johnson Pharmaceutical Research & Development LLC

    E-mail: info1@veritasmedicine.com

    NCT01098539

    A Study of the Efficacy and Safety of Albiglutide in Subjects with Type 2 Diabetes with Renal Impairment

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: GlaxoSmithKline

    Contact: US GSK Clinical Trials Call Center

    Phone: 877-379-3718

    NCT00938158

    A Study of the Pharmacokinetics of Albiglutide in Normal and Renally-Impaired Subjects

    Ages eligible for study: 30 years to 75 years

    Sponsors and collaborators: GlaxoSmithKline

    Contact: US GSK Clinical Trials Call Center

    Phone: 877-379-3718

    NCT01113801

    A Study in Patients with Diabetic Kidney Disease

    Ages eligible for study: 25 years and older

    Sponsors and collaborators: Eli Lilly and Company, and Collaborative Study Group (CSG)

    Phone: 877-CTLILLY (877-285-4559)

    NCT01043029

    A Study of Aleglitazar in Type 2 Diabetes Patients with Moderate Renal Impairment

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Hoffmann-La Roche

    Contact: Please reference Study

    ID Number: BC22419

    Phone: 888-662-6728

    E-mail: genentechclinicaltrials@druginfo.com

    Back to Top | Article Outline
    • Hemodialysis •

    NCT01228123

    Randomized Clinical Trial Comparing Continuous Versus Intermittent Hemodialysis in ICU Patients

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Charite University, Berlin

    Contact: Prof. Dr. Achim Joerres

    Phone: 49-30-450-665537

    E-mail: achim.joerres@charite.de

    Back to Top | Article Outline
    • Immunosuppression •

    NCT01132157

    Comparison of the Protective Effect of Desflurane and Propofol in Patients with Renal Transplantation

    Ages eligible for study: 20 years and older

    Sponsors and collaborators: Yonsei University

    Contact: Bon Nyeo Koo, MD, PhD

    Phone: 82-2-2228-2422

    E-mail: koobn@yuhs.ac

    NCT00811915

    Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation

    Ages eligible for study: 18 years to 76 years

    Sponsors and collaborators: Rouen University Hospital

    Contact: Caroline Freguin, MD

    Phone: 0232889152

    E-mail: caroline.freguin@chu-rouen.fr

    NCT00895583

    Study Evaluating a Planned Transition from Tacrolimus to Sirolimus in Kidney Transplant Recipients

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Wyeth

    Contact: Pfizer CT.gov Call Center

    Phone: 800-718-1021

    NCT00502242

    Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Renal Transplant Patients Converted to Sirolimus

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Wyeth

    Contact: Pfizer CT.gov Call Center

    Phone: 800-718-1021

    NCT00933231

    Comparison of Standard Versus Low-Dose Advagraf with or Without Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker on Histology and Function of Renal Allografts

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Astellas Pharma and Astellas Pharma Canada

    Contact: Astellas Pharma Canada Medical Information

    Phone: 888-338-1824

    NCT00565331

    Rituximab for Prevention of Rejection After Renal -Transplantation

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Radboud University, Hoffmann-La Roche, and Astellas Pharma GmbH

    Contact: Luuk Hilbrands, MD

    Phone: 312-431-4761

    E-mail: l.hilbrands@nier.umcn.nl

    NCT00752479

    Mesenchymal Stem Cells Under Basiliximab/Low-Dose RATG to Induce Renal Transplant Tolerance

    Ages eligible for study: 18 years to 80 years

    Sponsors and collaborators: Mario Negri Institute for Pharmacological Research

    Contact: Piero Ruggenenti, MD

    Phone: 0039 035 269296

    E-mail: pruggenenti@ospedaliriuniti.bergamo.it

    NCT01154387

    Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

    Ages eligible for study: 18 years to 60 years

    Sponsors and collaborators: Tolera Therapeutics

    Contact: Leslie O'Toole, RN

    Phone: 269-585-2100, ext. 2111

    E-mail: lotoole@tolera.com

    NCT01224860

    Telmisartan Versus Losartan in Kidney Transplantation

    Ages eligible for study: 18 years to 80 years

    Sponsors and collaborators: Mario Negri Institute for Pharmacological Research

    Contact: Paolo Cravedi, MD

    Phone: 0039-035-45351

    E-mail: paolo.cravedi@marionegri.it

    NCT00758602

    A Study of CellCept (Mycophenolate Mofetil) Combined with Tacrolimus and Corticosteroids in Kidney Transplant Patients

    Ages eligible for study: Up to 75 years

    Sponsors and collaborators: Hoffmann-La Roche

    Contact: Please reference Study

    ID Number: ML21740

    Phone: 888-662-6728

    E-mail: genentechclinicaltrials@druginfo.com

    NCT01236287

    Special Access for the Use of Voclosporin for Kidney Transplantation

    Ages eligible for study: 18 years to 65 years

    Sponsors and collaborators: Weill Cornell Medical College

    Contact: Meredith J. Aull, PharmD

    Phone: 212-746-5330

    E-mail: mea9008@med.cornell.edu

    NCT00782821

    Randomized Trial of Induction Therapies in High-Immunological-Risk Kidney Transplant Recipients

    Ages eligible for study: 18 years to 65 years

    Sponsors and collaborators: University of Cincinnati, Millennium Pharmaceuticals, and Genzyme

    Contact: Garth E. Wall

    Phone: 513-558-0289

    E-mail: garth.wall@uc.edu

    Back to Top | Article Outline
    • Transplantation •

    NCT00975000

    Treatment of Autonomous Hyperparathyroidism in Post-Renal-Transplant Recipients

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: Amgen

    Contact: Amgen Call Center

    Phone: 866-572-6436

    NCT00001858

    Monitoring for Tolerance to Kidney or Combined Kidney- Pancreas Transplants

    Sponsors and collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    Contact: Patient Recruitment and Public Liaison Office

    Phone: 800-411-1222

    E-mail: prpl@mail.cc.nih.gov

    NCT00592020

    Short Transverse Versus Conventional Hockey Stick Incision in Kidney Transplantation

    Ages eligible for study: 18 years and older

    Sponsors and collaborators: University Hospital Inselspital, Berne, Switzerland

    Contact: Daniel Inderbitzin, MD

    Phone: 0041316322111

    E-mail: daniel.inderbitzin@insel.ch

    © 2011 Lippincott Williams & Wilkins, Inc.